metaPreg - Tacrolimus (all routes) during pregnancy

Tacrolimus (all routes)

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.77 [1.05, 2.98]	0%	4 studies	58	490	not evaluable	ROB
1 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Preterm (< 37 weeks)	1.15 [0.51, 2.61]	71%	7 studies	718	577	not evaluable	ROB
Low birth weight (< 2500g)	1.07 [0.68, 1.69]	25%	4 studies	538	503	not evaluable	ROB
Small for gestational age (weight)	1.03 [0.29, 3.63]	0%	3 studies	19	29	not evaluable	ROB
1 non statistically significant endpoints reported in only one study
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Preeclampsia	1.01 [0.81, 1.25]	0%	8 studies	503	767	not evaluable	ROB
Caesarean	1.39 [1.00, 1.93]	17%	6 studies	769	572	not evaluable	ROB
Gestational diabete	1.58 [1.07, 2.34]	1%	5 studies	152	755	not evaluable	ROB
Maternal death	0.93 [0.15, 5.86]	0%	2 studies	5	117	not evaluable	ROB
3 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Neonatal death (< 28 days of life)	1.08 [0.43, 2.71]	0%	2 studies	19	442	not evaluable	ROB
2 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Early intrauterine death (< 22 weeks)	1.48 [0.70, 3.16]	37%	3 studies	324	678	not evaluable	ROB
Late intrauterine deaths (> 22 weeks)	0.65 [0.32, 1.33]	0%	4 studies	36	687	not evaluable	ROB
Therapeutic terminations of pregnancy	0.28 [0.14, 0.56]	-	1 study	68	602	not evaluable	ROB
3 non statistically significant endpoints reported in only one study